3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Graft vs Host Disease
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, Mantle-Cell
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Cyclophosphamide
14
fludarabine phosphate
13
ruxolitinib
9
Busulfan
9
Antilymphocyte Serum
9
fludarabine
8
Peripheral Blood Stem Cell Transplantation
8
Filgrastim
8
Whole-Body Irradiation
7
Cyclosporine
7
Tacrolimus
6
Radiotherapy
6
Mycophenolic Acid
6
Methylprednisolone
6
Methotrexate
5
Melphalan
5
Cytarabine
5
Cord Blood Stem Cell Transplantation
5
Azacitidine
5
Imatinib Mesylate
4
Alemtuzumab
4
ponatinib
3
parsaclisib
3
fedratinib
3
Stem Cell Transplantation
3
Rituximab
3
Granulocyte Colony-Stimulating Factor
3
Etoposide
3
Decitabine
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Myeloproliferative Disorders
×
Calcineurin Inhibitors
×
Clear all
NCT01749111
2017-03-03
CICLODECH
Hospital Israelita Albert Einstein
Phase 3
Terminated
3 enrolled